Find information on thousands of medical conditions and prescription drugs.

Kallmann syndrome

Kallmann syndrome is an example of hypogonadism (decreased functioning of the sex hormone-producing glands) caused by a deficiency of gonadotropin-releasing hormone (GnRH), which is created by the hypothalamus. Kallmann syndrome is also known as hypothalamic hypogonadism, familial hypogonadism with anosmia, or gonadotropic hypogonadism, reflecting its disease mechanism. more...

Kallmann syndrome
Kallmann syndrome
Kallmann syndrome
Kallmann syndrome
Kaposi sarcoma
Karsch Neugebauer syndrome
Kartagener syndrome
Kawasaki syndrome
Kearns-Sayre syndrome
Kennedy disease
Keratoconjunctivitis sicca
Keratosis pilaris
Kikuchi disease
Klinefelter's Syndrome
Klippel Trenaunay Weber...
Klippel-Feil syndrome
Klumpke paralysis
Kluver-Bucy syndrome
Kniest dysplasia
Kohler disease
Korsakoff's syndrome
Kostmann syndrome
Seborrheic keratosis

Kallman syndrome was described in 1944 by Franz Josef Kallmann, a German geneticist. However, others had noticed a correlation between anosmia and hypogonadism before this such as the Spanish doctor Aureliano Maestre de San Juan 80 years previously.


Kallmann syndrome is characterized by:

  • Hypogonadotropic hypogonadism (a lack of the pituitary hormones LH and FSH)
  • Congenital (present from birth) anosmia (complete inability to smell) or hyposmia (decreased ability to smell).

It can also be associated with optic problems, such as color blindness or optic atrophy, nerve deafness, cleft palate, cryptorchidism, renal agenesis, and mirror movement disorder. However, it is not clear at this time how or if these other problems have the same cause as the hypogonadism and anosmia and these other problems are more often present in those without Kallmann syndrome.

Males present with delayed puberty and may have micropenis (although congenital micropenis is not present in the majority of male KS cases).

Females present with delayed puberty i.e.primary amenorrhea and lack of secondary sex characteristicd, such as breast development.


The diagnosis is often one of exclusion found during the workup of delayed puberty. The presence of anosmia together with micropenis in boys should suggest Kallmann syndrome (although micropenis alone may have other causes).


Under normal conditions, GnRH travels to the pituitary gland via the tuberoinfundibular pathway, where it triggers production of gonadotropins (LH and FSH). When GnRH is low, the pituitary does not create the normal amount of gonadotropins. The gonadotropins in turn affect the production of hormones in the gonads, so when they are low, the hormones will be low as well.

In Kallmann syndrome, the GnRH neurons do not migrate properly from the olfactory placode to the hypothalamus during development. The olfactory bulbs also fail to form or have hypoplasia, leading to anosmia or hyposmia.

Kallman syndrome can be inherited as an X-linked recessive trait, in which case there is a defect in the KAL gene, which maps to chromosome Xp22.3. KAL encodes a neural cell adhesion molecule, anosmin-1. Anosmin-1 is normally expressed in the brain, facial mesenchyme, mesonephros and metanephros. It is required to promote migration of GnRH neurons from the hypothalamus to the pituitary gland. It also allows migration of olfactory neurons from the olfactory bulbs to the hypothalamus.


Treatment is directed at restoring the deficient hormones -- known as hormone replacement therapy (HRT). Males are administered human chorionic gonadotropin (hCG) or testosterone. Females are treated with oestrogen and progestins.


[List your site here Free!]

Evaluation of the subfertile man
From American Family Physician, 5/15/03 by Peter N. Kolettis

Infertility, defined as the inability to conceive after one year of unprotected intercourse, affects 15 percent of couples. It is not unreasonable, however, to begin a fertility evaluation sooner than one year if the woman's age is a factor and delaying the evaluation could further diminish the couple's chance of conceiving. Male subfertility is one of the most rapidly growing fields in medicine, with dramatic advances in diagnosis and treatment.

Although infertility (or subfertility) is often attributed to female causes, fertility is a two-person phenomenon. Successful conception depends on many complicated events, including satisfactory sexual and ejaculatory function, appropriate timing, and a complex set of interactions between the male and the female reproductive tracts. Male and female factors coexist in about one third of cases, while one third of cases are secondary to male factors only. (1) Therefore, evaluation of both partners is critical, and the woman's gynecologic evaluation should proceed simultaneously with the man's.

Causes of Male Subfertility

The most common identifiable cause of male subfertility is a varicocele, a condition of palpably distended veins of the pampiniform plexus of the spermatic cord. (1,2) The term "subclinical varicocele" refers to a lesion too small to be detected by physical examination. The concept of a subclinical varicocele arose from the observation in early reports that the detrimental effect of small varicoceles equaled that of larger varicoceles. However, more recent studies suggest that larger varicoceles have a greater impact on fertility. (3) As a result, most subspecialists who deal with male subfertility do not regard subclinical varicoceles as clinically significant.

Another common correctable cause of male subfertility is obstruction, which may occur after a vasectomy. (1,4) Less common correctable causes include ejaculatory dysfunction, infection, medications, and hormonal deficiency (Table 1). (1) When the sum of these correctable causes is calculated, it becomes apparent that more than one half of cases of male subfertility are potentially correctable.

In addition, specific corrective treatments such as vasectomy reversal and varicocele ligation are more cost effective than empiric treatment with assisted reproductive technologies. (5-7) Furthermore, correction of underlying male factors can allow for natural conception, does not carry an increased risk of multiple births, and spares the woman invasive procedures and the potential complications of these therapies. (8)

Recent advances, particularly in molecular genetics, have improved our understanding of some forms of male subfertility. A significant proportion of male subfertility currently is unexplained. About 13 percent of men with nonobstructive azoospermia (i.e., no sperm in the semen because of low or absent sperm production) have been shown to have Y-chromosome microdeletions, and about 70 percent of men with congenital bilateral absence of the vas deferens are carriers of cystic fibrosis mutations. (9-13)

The most significant advance in the treatment of severe male infertility is in vitro fertilization with intracytoplasmic sperm injection (ICSI). (14) With this technique, a single sperm is injected directly into the oocyte, circumventing severely decreased sperm quantity or quality. Only one viable sperm per egg is required for ICSI, and a precise diagnosis is not required to achieve conception. (15)

When using sperm from men with known or presumed genetic infertility, it must be assumed that any male offspring also will be infertile. Y-chromosome microdeletions from the father are inherited by the sons when ICSI is used. (16,17) Counseling about these potential genetic issues is a critical part of the male fertility evaluation. Because ICSI bypasses normal natural selection, concerns have been raised about the offspring. There does not appear to be an increased risk of major malformations in children born from ICSI compared with the general population. (18)


The main goals of evaluating the subfertile man are to identify correctable causes of infertility and to help him and his partner conceive by the most natural, least invasive means possible. In addition, the evaluation may uncover significant underlying medical or genetic pathology. Subfertility may be related to an underlying malignancy, such as a testicular or pituitary tumor. Other medical problems that significantly affect the health of the man or his offspring may be discovered. (19,20) If the only evaluation is a semen analysis, underlying pathology can be missed. Finally, many men seek an explanation for their condition, of which they may be deprived without a complete evaluation. (21)

History and Physical Examination

A careful history can offer clues to the underlying cause of infertility and provide an assessment of the man's fertility potential. The duration of the infertility, previous evaluation and treatment, previous pregnancies (for either partner), and any difficulty establishing these pregnancies should be documented. Inadequate frequency or timing of intercourse, sexual dysfunction, and lubricant use can impede pregnancy. The optimal frequency of intercourse is every day or every other day around the expected time of ovulation. (22) [Evidence level B, uncontrolled clinical trial] Because nearly all commercially available lubricants are spermatotoxic, their use is discouraged. (1)

Most men of reproductive age do not have a significant medical history, but some specific risk factors may be identified. For example, diabetes mellitus can cause erectile and ejaculatory dysfunction. Previous disorders of the testes, such as cryptorchidism or spermatic cord torsion, or a history of inguinal, scrotal, or retroperitoneal surgery, are associated with subfertility. Use of prescription or illicit drugs and exposure to environmental toxins also can impair fertility (Table 2). (1,23,24) In the review of systems, anosmia may suggest an underlying hypothalamic etiology (such as Kallmann's syndrome) or a pituitary etiology, while frequent respiratory infections are a feature of Young's syndrome (e.g., chronic sinusitis, bronchiectasis, obstructive azoospermia) and Kartagener's syndrome (e.g., primary ciliary dyskinesia/immotile cilia, chronic sinusitis, bronchiectasis, situs inversus). Headaches, visual field disturbances, or galactorrhea should prompt an investigation for a tumor of the central nervous system1 (Table 3).

A thorough examination can identify underlying causes of subfertility. Abnormal distribution of hair and fat can suggest an underlying endocrinopathy, such as hypogonadotropic hypogonadism. The position and size of the urethral meatus should be noted because severe hypospadias can impair sperm deposition near the cervix. Normal testes are 20 cm or more or at least 4 cm in greatest dimension. Those smaller than 20 cm are suggestive of decreased sperm production and may occur in hypogonadal men as well.1 The presence of the vasa deferentia and epididymides as well as any induration or engorgement suggestive of obstruction should be noted.

Varicoceles are found most commonly on the left side, but up to 20 percent may be bilateral. Diagnosis should be made in a warm room by palpation of the spermatic cord with the patient in the standing position. Varicoceles are graded 1+ (palpable with Valsalva's maneuver only), 2+ (palpable), and 3+ (visible through the scrotal skin). An isolated right-sided varicocele or a lesion on either side that does not disappear when the patient assumes the supine position should prompt imaging of the retroperitoneum to evaluate for inferior vena caval or renal vein obstruction. Digital rectal examination is performed to examine the prostate gland, seminal vesicles, and possible cysts that can cause ejaculatory duct obstruction. Table 3 presents clinical clues to and possible diagnoses of male infertility.

Laboratory Evaluation

The semen analysis is the foundation of the laboratory evaluation. At least two samples, preferably taken at least two or three weeks apart, should be analyzed after two to three days of sexual abstinence. The sample should be collected by masturbation in a clean container and analyzed within one hour of collection. The sample can be collected at home if it is kept at body temperature and brought to the laboratory in sufficient time. (25)

Normal semen parameters, as defined by the World Health Organization, are summarized in Table 4. (26) In addition to the number of sperm per mL (concentration), other parameters, such as motility, are important in assessing a man's fertility potential. (26)

Leukocytospermia, which is defined as more than 1 million white blood cells per mL of semen, requires specific testing. It is not possible to definitively identify these cells by microscopic appearance alone. (27) In the presence of significant leukocytospermia, empiric antibiotic therapy is reasonable. Doxycycline (Vibramycin), in a dosage of 100 mg twice a day for two weeks, is an effective regimen. A repeat semen analysis should be performed at the completion of therapy.

The semen analysis does not test fertility, but rather fertility potential. The chance of initiating a pregnancy correlates with the total number of moving sperm. (28) Pregnancies can be established with subnormal parameters, illustrating the importance of the female partner's fertility potential and the fact that an abnormal semen analysis cannot be equated with subfertility. The morphology is a measurement of the percentage of the normal-shaped sperm. The Kruger or strict morphology score has been correlated with decreased success with fertilization in vitro. The significance of this finding in estimating the chance for natural conception is less clear. As with any other single semen parameter, it cannot be used in an absolute way to predict fertility. (29)

A semen analysis does not assess sperm function. Specialized testing is available to evaluate this factor, and the test of choice varies among treatment centers. Most tests attempt to examine some component of sperm-oocyte interaction or fertilization. Interpretation of these test results can be difficult, and the question of whether the results influence clinical management is controversial. These tests generally are performed only in specialized fertility laboratories.

Male subfertility caused by correctable endocrinopathies is rare. As such, hormone testing for all subfertile men is not necessary. When sperm concentration is less than 10 million per mL, measurement of the serum testosterone and follicle-stimulating hormone (FSH) levels is indicated. (30) The levels of serum testosterone and FSH are adequate to assess the pituitary-testicular axis in the majority of cases. If the total testosterone level is normal, no further endocrine testing is needed. If the total testosterone level is low, the serum luteinizing hormone and prolactin levels can be checked to evaluate for a pituitary cause.

When testosterone is merely borderline or only slightly low, supplementation should be avoided unless the man is significantly symptomatic (i.e., erectile dysfunction, markedly decreased energy level, lack of libido). Testosterone supplementation will actually lower the sperm concentration in such men because it can cause pituitary suppression of gonadotropins. In the setting of subfertility, the FSH level may be elevated, suggesting end-organ (testicular) failure. A low level may indicate an underlying FSH deficiency, such as occurs with hypogonadotropic hypogonadism (Table 3).

More specialized testing may be required based on the outcome of this initial evaluation (Figure 1). Most specialized testing requires referral to a center with clinical and laboratory expertise in the field of reproductive medicine. For example, men with low ejaculate volume (less than 1 mL) should have a post-ejaculatory urine sample analysis to rule out retrograde ejaculation. Azoospermic men can undergo testicular biopsy to evaluate the level of sperm production and differentiate between testicular failure and obstruction (i.e., normal sperm production). In patients with azoospermia, low semen volume (less than 1 mL), and a normal FSH level, transrectal ultrasonography is indicated to evaluate for possible ejaculatory duct obstruction (31) (Figure 2). (32)


Genetic testing and counseling are indicated in specific instances. In patients with azoospermia or severe oligospermia, the karyotype should be determined because of the increased incidence of karyotypic abnormalities in this population. (10) Men with congenital absence of the vas deferens, either unilateral or bilateral, may be carriers of cystic fibrosis. These men and their partners should undergo testing for cystic fibrosis mutations. (11,12) These men also should have abdominal ultrasonography to check for renal agenesis.

The outcome of the initial evaluation can help guide treatment. If correctable causes are found, specific corrective treatment is offered. If no correctable problem exists, the couple may wish to pursue treatment with assisted reproductive technologies such as intrauterine insemination. (33) An alternative to assisted reproductive technologies is empiric treatment with clomiphene citrate (Serophene), although few convincing data show benefit. (34) Some reproductive subspecialists advocate abandoning the male evaluation, with the exception of the semen analysis. Whether this is an efficient approach to conception is debatable, but denying the man an evaluation, including an opportunity to learn the cause of his problem and the chance for specific corrective therapy, seems inappropriate. (20,21)

The author indicates that he does not have any conflicts of interest. Sources of funding: none reported.


(1.) Sigman M, Lipshultz LI, Howards SS. Evaluation of the subfertile male. In: Lipshultz LI, Howards SS, eds. Infertility in the male. 3d ed. St. Louis: Mosby, 1997:173-93.

(2.) World Health Organization. The influence of varicocele on parameters of fertility in a large group of men presenting to infertility clinics. Fertil Steril 1992;57:1289-93.

(3.) Steckel J, Dicker AP, Goldstein M. Relationship between varicocele size and response to varicocelectomy. J Urol 1993;149:769-71.

(4.) Belker AM, Thomas AJ Jr, Fuchs EF, Konnak JW, Sharlip ID. Results of 1,469 microsurgical vasectomy reversals by the Vasovasostomy Study Group. J Urol 1991;145:505-11.

(5.) Kolettis PN, Thomas AJ Jr. Vasoepididymostomy for vasectomy reversal: a critical assessment in the era of intracytoplasmic sperm injection. J Urol 1997; 158:467-70.

(6.) Pavlovich CP, Schlegel PN. Fertility options after vasectomy: a cost-effectiveness analysis. Fertil Steril 1997;67:133-41.

(7.) Schlegel PN. Is assisted reproduction the optimal treatment for varicocele-associated male infertility? A cost-effectiveness analysis. Urology 1997;49:83-90.

(8.) Schenker JG, Ezra Y. Complications of assisted reproductive techniques. Fertil Steril 1994;61:411-22.

(9.) Reijo R, Lee TY, Salo P, Alagappan R, Brown LG, Rosenberg M, et al. Diverse spermatogenic defects in humans caused by Y chromosome deletions encompassing a novel RNA-binding protein gene. Nat Genet 1995;10:383-93.

(10.) Van Assche E, Bonduelle M, Tournaye H, Joris H, Verheyen G, Devroey P, et al. Cytogenetics of infertile men. Hum Reprod 1996;11(suppl 4):1-26.

(11.) Anguiano A, Oates RD, Amos JA, Dean M, Gerrard B, Stewart C, et al. Congenital bilateral absence of the vas deferens. A primarily genital form of cystic fibrosis. JAMA 1992;267:1794-7.

(12.) Jaffe T, Oates RD. Genetic aspects of infertility. In: Lipshultz LI, Howards SS, eds. Infertility in the male. 3d ed. St. Louis: Mosby, 1997:280-304.

(13.) Mak V, Jarvi KA. The genetics of male infertility. J Urol 1996;156:1245-56.

(14.) Palermo G, Joris H, Devroey P, Van Steirteghem AC. Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. Lancet 1992; 340:17-8.

(15.) Sherins RJ, Thorsell LP, Dorfmann A, Dennison-Lagos L, Calvo LP, Krysa L, et al. Intracytoplasmic sperm injection facilitates fertilization even in the most severe forms of male infertility: pregnancy outcome correlates with maternal age and number of eggs available. Fertil Steril 1995;64:369-75.

(16.) Page DC, Silber S, Brown LG. Men with infertility caused by AZFc deletion can produce sons by intracytoplasmic sperm injection, but are likely to transmit the deletion and infertility. Hum Reprod 1999; 14:1722-6.

(17.) de Vries JW, Repping S, Oates R, Carson R, Leschot NJ, van der Veen F. Absence of deleted in azoospermia (DAZ) genes in spermatozoa of infertile men with somatic DAZ deletions. Fertil Steril 2001; 75:476-9.

(18.) Bonduelle M, Camus M, De Vos A, Staessen C, Tournaye H, Van Assche E, et al. Seven years of intracytoplasmic sperm injection and follow-up of 1987 subsequent children. Hum Reprod 1999; 14(Suppl 1):243-64.

(19.) Honig SC, Lipshultz LI, Jarow J. Significant medical pathology uncovered by a comprehensive male infertility evaluation. Fertil Steril 1994;62:1028-34.

(20.) Kolettis PN, Sabanegh ES. Significant medical pathology discovered during a male infertility evaluation. J Urol 2001;166:178-80.

(21.) Cummins JM, Jequier AM. Treating male infertility needs more clinical andrology, not less. Hum Reprod 1994;9:1214-9.

(22.) Wilcox AJ, Weinberg CR, Baird DD. Timing of sexual intercourse in relation to ovulation. Effects on the probability of conception, survival of the pregnancy, and sex of the baby. N Engl J Med 1995; 333:1517-21.

(23.) Kolettis PN, Thomas AJ. Andrology. In: Ransom SB, Dombrowski MP, eds. Practical strategies in obstetrics and gynecology. Philadelphia: Saunders, 2000: 631.

(24.) Hakim LS, Oates RD. Nonsurgical treatment of male infertility: specific therapy. In: Lipshultz LI, Howards SS, eds. Infertility in the male. 3d ed. St. Louis: Mosby, 1997:395-402.

(25.) Overstreet JW, Brazil C. Semen analysis. In: Lipshultz LI, Howards SS, eds. Infertility in the male. 3d ed. St. Louis: Mosby, 1997:487-90.

(26.) World Health Organization. Reference values of semen variables. In: WHO laboratory manual for the examination of human semen and sperm-cervical mucus interaction. 4th ed. Cambridge: Cambridge University Press, 1999:60-1.

(27.) Anderson DJ. Semen white blood cell assay. In: Lipshultz LI, Howards SS, eds. Infertility in the male. 3d ed. St. Louis: Mosby, 1997:509-11.

(28.) Schoysman R, Gerris J. Twelve-year follow-up study of pregnancy rates in 1291 couples with idiopathically impathically impaired male fertility. Acta Eur Fertil 1983;14:51-6.

(29.) Kruger TF. Strict criteria for sperm morphology. In: Lipshultz LI, Howards SS, eds. Infertility in the male. 3d ed. St. Louis: Mosby, 1997:491-3.

(30.) Sigman M, Jarow JP. Endocrine evaluation of infertile men. Urology 1997;50:659-64.

(31.) Goluboff ET, Stifelman MD, Fisch H. Ejaculatory duct obstruction in the infertile male. Urology 1995;45:925-31.

(32.) Kolettis PN. The evaluation and management of the azoospermic patient. J Androl 2002;23:293-305.

(33.) Guzick DS, Carson SA, Coutifaris C, Overstreet JW, Factor-Litvak P, Steinkampf MP, et al. Efficacy of superovulation and intrauterine insemination in the treatment of infertility. N Engl J Med 1999; 340:177-83.

(34.) Jarow JP. Nonsurgical treatment of male infertility: empiric therapy. In: Lipshultz LI, Howards SS, eds. Infertility in the male. 3d ed. St. Louis: Mosby, 1997: 410-22.

PETER N. KOLETTIS, M.D., is assistant professor of surgery in the Division of Urology at the University of Alabama at Birmingham. Dr. Kolettis received his medical degree from the University of Chicago Pritzker School of Medicine and completed a residency in urology and a fellowship in male infertility at the Cleveland Clinic Foundation.

Address correspondence to Peter N. Kolettis, M.D., Department of Surgery, Division of Urology, University of Alabama at Birmingham, 1530 Third Ave. South, MEB 606, Birmingham, AL 35294-3296. Reprints are not available from the author.

COPYRIGHT 2003 American Academy of Family Physicians
COPYRIGHT 2003 Gale Group

Return to Kallmann syndrome
Home Contact Resources Exchange Links ebay